Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 27;11(8):828–840. doi: 10.1093/stcltm/szac041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — IV and IT delivered WJ-MSC EVs have similar lung protective effects in BPD and PH. IT and IV WJ-MSC EVs significantly reduced (A) weight ratio of the right ventricle to left ventricle + septum (RV/LV+S). (B) Representative lung sections stained with Von Willebrand Factor (green) and α-smooth muscle actin (red) showing increased vessels and decreased muscularization in both IV and IT hyperoxia WJ-MSC EV treated groups. Original magnification 10×. (C) Similar improvement in lung vascular density and (D) percentage of muscularized vessels in both IV and IT hyperoxia WJ-MSC EV groups. (E) H&E-stained lung sections demonstrating improved alveolar structure in hyperoxia-exposed rats that received IV or IT WJ-MSC EV. Original magnification 10×. Morphometric analysis showing (F) similarly decreased mean linear intercept in IT and IV WJ-MSC EV treated hyperoxia rats. Data are presented as mean ± SEM; N = 8–16/group. *P < .05; room air placebo (PL) vs. hyperoxia PL or hyperoxia PL vs. hyperoxia IT or hyperoxia IV WJ-MSC EV. Room air: open bar; hyperoxia: gray bar.